Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:

Abstract: The present invention relates to novel compounds of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (?) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.

Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.

Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

Abstract: The present disclosure relates to a novel combination of compounds, their use as antibacterials, compositions comprising them and methods for treating or preventing bacterial infections, more particularly, bacterial infections caused by Gram-negative pathogens and/or drug resistant Gram-negative bacteria.

Abstract: Described herein are new approaches to antimicrobial therapy, which includes the development of new combinations of antibiotic agents as well as their use for specific therapeutic purposes. These specific therapeutic purposes may apply to clinical situations inherently different from treatment of infections that require systemic antibiotic administration. More localized approaches offer a number of advantages. The advantages of such antibiotic combinations include, but are not limited to, targeting a broader spectrum of microbes; faster microbial eradication; sparing the subject systemic exposure to the individual antimicrobial agents; enhancing the antimicrobial activity against microbes considered resistant to individual agents; and enhancing the antimicrobial activity against microbes considered resistant to individual agents at levels appropriate for systemic administration.

Abstract: An intravenous pharmaceutical composition or kit comprising 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound I) and a beta-cyclodextrin derivative.

Abstract: The invention relates to methods for preventing stress-associated disorders. These disorders may be treated with a serotonin 2c receptor (5-HT2CR) antagonist prior to, during, or following a stress-related event. Stress-associated disorders include, for instance, post-traumatic stress disorder (PTSD).

Abstract: It has been authoritatively noted that after 100 years of cancer research, the life expectancy in most cancers has only increased by about 3 months. New, effective treatments for cancer are badly needed. The present invention relates to methods to use high doses of Dehydroepiandrosterone, doses sufficient to inhibit tumor Glucose-6-Phosphate Dehydrogenase and thereby deplete tumor NADP(H) pools, with a reconstitution mixture that replenishes metabolites required by normal tissues, thereby avoiding side effects that would otherwise occur. The combination of High Dose Dehydroepiandrosterone and the reconstitution mixture is termed Naturasone™, and its use is described herein both as a replacement for prednisone, and as a standalone cancer medication.

Abstract: The low steroid hormone levels of neutered or aging mammals is associated with a dramatic increase in risk of cancer. This invention pertains to a natural method of replenishing the low steroid hormone levels of neutered or aging mammals, levels that are associated with high cancer risk, to levels of those of non-neutered or young animals, levels that are associated with a low cancer risk. The invention also pertains to methods of maintaining healthy levels of several important natural metabolites that can become depleted during the steroid hormone replenishment process.

Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract: Methods and pharmaceutical compositions are provided for enhancing or stimulating regeneration of a tissue in a subject. In one aspect, the invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an aminosterol or a pharmaceutically acceptable salt thereof to stimulate or enhance regeneration of a tissue. In another aspect, the invention provides a method including administering to a subject a therapeutically effective amount of an aminosterol or a pharmaceutically acceptable salt thereof to stimulate or enhance regeneration of a tissue to treat or prevent a disease, disorder, trauma, or condition resulting from an injury of the tissue. In an additional aspect, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of an aminosterol to stimulate or enhance regeneration of a tissue.

Abstract: The invention provides method and composition for alleviating one or more symptoms associated with a medical condition mediated by one or more of a cyclooxygenase, a pro-inflammatory cytokine, and a pro-inflammatory enzyme. The method includes administering an effective amount of a composition to a person suffering from the medical condition. The composition essentially includes a set of plant extracts. The set of plant extracts include an extract of Withania somnifera, an extract of Boswellia serrata, an extract of Curcuma longa, and an extract of Zingiber officinale. Wherein, one or more extracts of the set of plant extracts includes one or more desired active ingredient in an amount greater than an amount of other active ingredients present in the one or more extracts. The composition can also be used as combination therapy with any other known anti-inflammatory agents.

Abstract: Provided is a slow release composition to promote bone growth, the slow release composition comprising: an oxysterol encapsulated in a biodegradable polymer to control the release of the oxysterol. Methods of making and use are further provided.

Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.

Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.

Abstract: The present disclosure provides a composition and method for promoting functional neuronal development in pediatric subjects. The composition comprises in some embodiments up to about 7 g/100 Kcal of a fat or lipid source; up to about 5 g/100 Kcal of a protein source; about 3 mg/100 Kcal to about 50 mg/100 Kcal of phosphatidylethanolamine; about 0.15 mg/100 Kcal to about 75 mg/100 Kcal of sphingomyelin; and about 5 mg/100 Kcal to about 75 mg/100 Kcal of docosahexaenoic acid. The methods comprise, in some embodiments, administering the aforementioned composition to a pediatric subject.

Abstract: The disclosure relates to dietary supplement compositions and methods of use thereof comprising L-arabinose and one or more select compounds, which may include one or more select phytochemical compounds. The claimed compositions are useful in dietary supplements to facilitate mitigating elevated blood sugar levels and managing a user's weight as well as enhancing performance of digestive system to prevent inflammation and infection.

Abstract: The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. RYGB, as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome.

Abstract: Disclosed herein is a method for alleviating radiation injury, which includes administering to a subject in need thereof a composition containing isorhamnetin-3-O-?-D-glucoside.

Abstract: Described herein are methods for the prevention of neurodegeneration and the treatment of neurodegenerative disease (Including amyotrophic lateral sclerosis) ami neurodevelopmental disorders through the administration of an agent that inhibits die a2-Na/K ATPase/a-Adducin Complex.

Abstract: Methods of treating an arthritic joint of a subject, including administering a pharmaceutical composition by injection into the arthritic joint, wherein the composition includes an anthocyanin or anthocyanidin, glucose, and a pharmaceutically acceptable carrier.

Abstract: Methods of treating a subject suffering from an ocular infection and/or ocular inflammation are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least two active agents in an ophthalmically acceptable vehicle that can provide a sustained release of the at least two active agents. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.

Abstract: The present invention relates to a microbubble complex comprising a microbubble having an outer shell comprising a mixture of native and denatured albumin encapsulating a perfluorocarbon gas, a therapeutic agent, a bifunctional linker having one end attached to the therapeutic agent and the other attached to a ligand and wherein the ligand is bound to the other shell of the microbubble through hydrophobic interactions. Also included are methods for delivering the aforementioned microbubble complex to a tissue target.

Abstract: The object of the invention is to provide a pharmacological ophthalmic composition for use in the correction of presbyopia as a drop introduced onto the surface of the eye and surrounding soft tissue (drops) or as an implant surgically introduced into the subconjunctival space with sustained slow release application.

Abstract: The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients.

Abstract: This invention relates, e.g., to a composition comprising two or more of: (a) N-acetylcysteine and/or (b) simethicone and/or (c) a docusate salt. In one embodiment of the invention, the amounts of (a) and/or (b) and/or (c) are effective, when the composition is administered into a colon of a subject undergoing colonoscopy, to cleanse a region of the colon in the visual field of the colonoscope so that the region contains no adherent stool or intestinal secretions obscuring the visual field. Methods for using this or other compositions of the invention, e.g. to cleanse the colon of a subject in order to enhance visualization of the colon during a colonoscopy, are also described, as are kits for carrying out methods of the invention.

Abstract: A method and system for extraction of moomiyo from a multi-component, naturally-occurring mineral substance generally found in Asian mountain ranges at elevations approximately between 1000 and 5000 meters. Bio-active compounds are extracted from said mineral substance for the medicinal applications including at least one of joint pain relief, skin care, anti-inflammation, bruise removal, decrease high blood cholesterol and high triglycerides levels, promotion of mental and physical energy, regulation of blood sugar levels, stimulation of the immune system, speeding of the recovery from sickness and wound healing therapies.

Abstract: A medicament for treatment of hypertension based on anion and traditional Chinese medicine, containing active ingredients by percentage weight, which are: 9˜30% of Scutellaria baicalensis, 3˜9% of Radix Bupleuri, 3˜12% of Uncaria tomentosa (cat's claw), 3˜9% of Ginseng, 15˜25% of Cynanchum mooreanum Hemsl., 3˜9% of Cordyceps sinensis (Berk.) Sacc., 10˜15% of Flastem Milkvetch Seed, 9˜15% of Dermatocarpon miniatum(L.)Mann. [Lichen miniatius L.], 10˜15% of Millettia dielsiana, 10˜15% of stem or root of Dalbergia hancei Benth. (Leguminosae), 1˜4% of anion powder and 1˜4% of far-infrared nano powder. Through the use of far infrared nano powder and anion powder with low cost and easily obtainable traditional Chinese medicine, the traditional Chinese medicine is further strengthened with increased efficacy while the far infrared and anion promotes blood circulation and cell repair, which in turn further increases the efficacy and treatment result.

Abstract: The present application discloses a method of synthesizing metal-based cationic surfactants and further their usage as anti-tumor and anti-bacterial agents. For the synthesis, selenius acid is mixed with sulfonamide to form sulfonammonium hydrogen selenites. Cobalt and Platinum hydrogen selenite dehydrate were then synthesized, and refluxed with sulfonammonium hydrogen selenites to form the disclosed Cobalt/Platinum ammonium hydrogen selenite complexes. Both complexes were mixed with cyclodextrin oligosaccharide to form nanoparticles, which were tested for anti-tumor/cancer and anti-bacterial effects.

Abstract: Methods of treating gastro-esophageal reflux disease in a subject are provided. The methods can include administering an effective amount of a formulation to treat the gastroesophageal reflux disease, the formulation having a water soluble tannin combined with hydrogen peroxide in a pharmaceutically acceptable excipient; wherein, the tannin has a molecular weight ranging from about 170 Daltons to about 4000 Daltons; the tannin:peroxide weight ratio ranges from about 1:1000 to about 10:1; and, the composition at least inhibits a gastrointestinal spasm associated with gastroesophageal reflux disease in the subject when compared to a second subject in a control group in which the composition was not administered.

Abstract: The present invention relates to a method of treating a neoplastic condition in a mammal. More particularly, the present invention is directed to a method of treating solid tumours, such as primary tumours, secondary tumours, and metastatic tumours. The method of the present invention is predicated on down-regulating the growth of neoplastic cells by administering stem cells or a population of multilineage progenitor cells (MLPC) which have been generated in vitro.

Abstract: Provided herein, for example, are methods generally relating to the expansion and/or regeneration of central nervous system (CNS) cells, such as nerve cells, astrocytes and oligodendrocytes, using an activator of cereblon (CRBN), such as an inhibitor of a CRBN substrate or downstream protein. Also provided herein, for example, are methods related to the expansion of neural stem cells, neural progenitor cells, or neural precursor cells and/or differentiation of these cells into CNS cells using a BRD7 antagonist, Ikaros antagonist, or CRBN activator. In certain embodiments, the methods further comprise differentiation of certain stem cells into the neural stem cells, neural progenitor cells, or neural precursor cells using a BRD7 antagonist, Ikaros antagonist, or CRBN activator. Also provided herein, for example, are methods of preventing or treating a CNS cell defective disease, disorder or condition, or a symptom thereof, using a BRD7 antagonist, Ikaros antagonist, or CRBN activator.

Abstract: Methods and apparatuses are disclosed for the treatment of diabetes using artificial islets of Langerhans. In one example, the artificial islet of Langerhans include islets or stem cells (but can also include hepatocytes or even any biological cell type) encapsulated in alginate microcapsules. The microcapsules can then be shrunk to reduce dead space between the capsules and the cells by incubating at physiological human temperatures and/or alginate crosslinking in the presence of barium chloride.

Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.

Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.

Abstract: The present invention is directed to polypeptides and compositions thereof useful for the prevention or treatment of an inflammatory bowel disease in particular Crohn's disease or ulcerative colitis (UC), and of coeliac disease. More particularly, the invention relates to agents and compositions thereof that useful for the prevention and treatment of hypersensitivity and/or hyperirritability of the colon and/or small intestine.

Abstract: The Lactobacillus paracasei MCC1849 (NITE BP-01633) strain, which has a high IL-12 production-promoting action, is used as an ingredient of a drug, food or drink, or feed used for promotion of IL-12 production, immunostimulation, antivirus, or the like.

Abstract: Some embodiments of the invention include an energy composition. In some embodiments, the energy composition may include an herb such as Mormon tea, a methylxanthine such as theobromine, and an active ingredient such as phenylethylamine HCl.

Abstract: This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.

Abstract: Provided are a pharmaceutical composition for preventing or treating skin cancer and a method of preventing or treating skin cancer in a subject by using the pharmaceutical composition, wherein the pharmaceutical composition includes a Panax spp. plant extract as an active ingredient.

Abstract: The present invention relates to the use of an extract of a Vernonia plant from Madagascar in cosmetics, pharmaceuticals and food supplements for improving the skin status, more specifically by strengthening the dermal-epidermal junction and/or by activating fibroblasts synthesis of dermis and extracellular matrix compounds.

Abstract: The present invention relates to a composition for relieving one or more of the conditions of pain, stress and insomnia comprising Brassica compestris, Bees wax and Dryobalanops camphora. The present invention also provides a formulation comprising the composition of the present invention as well as method for preparation thereof, uses thereof and method of treatment of one or more of the conditions of pain, stress and insomnia.

Abstract: The present invention is a diffusional patch having an oil mixture (20) providing mechanical treatment support by reducing the edema in volume and in mass by throwing out the liquid inside by means of diffusion effect after entering into the region with edema by means of the diffusion effect and placed into a porous sheath (10) in microfiber structure, in order to be used in treatment of region with edema which may occur in sports injuries and/or disc hernia (50); characterized in that said oil mixture (20), of which the ingredient proportions in weight are given, comprises the below mentioned ingredients and does not comprise water: Ingredient Amount (%) Dextrin Palmitate Derivatives 1-10 Paraffin 1-30 Oleum nigellae sativae (black cumin oil) 0-20 Oleum origani (carvacrol) 0-20 Oleum lauri expressum (laurel oil) 0-30 Oleum chamomillae (chamomile oil) 0-30 Balsamum meccae (balsam oil) 0-30 Styrax liguidus (sweetgum) 0-30 Oleum limonis (lemon oil) 0-10 Oleum rosmarini (rosemary oil) 0-10 Olive oil 0-30 Oleum v

Abstract: The invention relates to a herbal preparation for a treatment of wounds, skin inflammations and chronic and inflammatory complications after a surgery. The herbal preparation comprises an extract of Melittis melissophyllum L. emulsified or suspended in an organic medium from 10% to 40% by weight, and ethyl alcohol from 10% to 20% by weight. In case of an ointment as the organic medium was used Vaseline album from 40% to 70% by weight, in case of a gel—glycerol or propylene glycol 2% by weight, triethylamine 2% by weight, hydroxycellulose 1% by weight, and purified water (aqua purificata) from 30% to 35% by weight.

Abstract: An extract from green coffee beans is disclosed which contains polyphenols and bioactive compounds e.g. Chlorogenic acids in a significantly higher concentration (70-80%) than in extracts of prior art methods (40-50%). The extract has greater ability to quench oxidative stress and destroy free radicals and offers health benefits due to its anti-obesity, anti-diabetic, antihypertensive, anti-tumor and anti-acid properties. The higher concentration of bioactive compounds has been achieved by use of polar solvents having polarity less than that of alcohols used for extraction. The use of such solvents of lower polarity such as n-Butyl alcohol, ethyl acetate or acetone results in extraction of enriched Chlorogenic acid fractions into the extract, leaving polar impurities behind in aqueous medium. The extract obtained has significantly higher content of polyphenols and chlorogenic acids ranging from 70-80% and a distinctive HPLC profile.